Clinical Relevance of CYP2D6 Genetics for Tamoxifen Response in Breast Cancer.
Tamoxifen is a standard endocrine therapy for the prevention and treatment of steroid hormone receptor-positive breast cancer. Tamoxifen requires enzymatic activation by CYP 450 enzymes for the formation of clinically relevant metabolites, 4-OH-tamoxifen and endoxifen, which both have a greater affinity to the estrogen receptor and ability to inhibit cell proliferation when compared to the parent drug. CYP2D6 is the key enzyme in this biotransformation, and recent mechanistic, pharmacologic, and clinical pharmacogenetic evidence suggests that genetic variants and drug interaction by CYP2D6 inhibitors influence plasma concentrations of active tamoxifen metabolites and outcome of patients treated with adjuvant tamoxifen. Particularly, non-functional (poor metabolizer) and severely impaired (intermediate metabolizer) CYP2D6 variants are associated with higher recurrence rates. Accordingly, CYP2D6 genotyping prior to treatment for prediction of metabolizer status and outcome may open new avenues for the individualization of endocrine treatment choice and benefit. Moreover, strong CYP2D6 inhibitors such as the selective serotonin reuptake inhibitor paroxetine should be avoided as co-medication.
Brauch
Hiltrud
H
Dr. Margarete Fischer Bosch Institute of Clinical Pharmacology Stuttgart and University Tübingen, Germany.
Schroth
Werner
W
Eichelbaum
Michel
M
Schwab
Matthias
M
Harbeck
Nadia
N
Pharmacogenetics. 1997 Jun;7(3):187-91
9241658
Breast Cancer Res Treat. 2008 Apr;108(3):421-6
17541741
Ann Oncol. 2007 Jul;18(7):1133-44
17675394
J Pharmacol Exp Ther. 1996 Jul;278(1):441-6
8764380
Pharmacogenet Genomics. 2006 Oct;16(10):755-66
17001295
J Clin Oncol. 2007 Sep 1;25(25):3837-45
17761971
J Natl Cancer Inst. 2005 Jan 5;97(1):30-9
15632378
J Endocrinol. 1977 Nov;75(2):305-16
591813
J Natl Cancer Inst. 2003 Dec 3;95(23):1758-64
14652237
Naunyn Schmiedebergs Arch Pharmacol. 2004 Jan;369(1):23-37
14618296
J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75
15159443
Lancet. 2005 Jul 30-Aug 5;366(9483):409-21
16054942
Clin Pharmacol Ther. 2006 Jul;80(1):61-74
16815318
Breast Cancer Res. 2007;9(1):R7
17244352
Breast Cancer Res. 2005;7(3):R284-90
15987423
Breast Cancer Res Treat. 2005 Jun;91(3):249-58
15952058
J Clin Oncol. 2006 Aug 1;24(22):3708-9; author reply 3709
16877740
Breast Cancer Res Treat. 2004 May;85(2):151-9
15111773
Ann Oncol. 2007 May;18(5):859-67
17301074
Breast Cancer Res Treat. 1982;2(2):123-38
6184101
Cancer Res. 1989 Apr 15;49(8):2175-83
2702659
Lancet. 2005 May 14-20;365(9472):1687-717
15894097
J Natl Cancer Inst. 2005 Nov 16;97(22):1652-62
16288118
J Pharmacol Exp Ther. 2006 Aug;318(2):503-12
16690721
J Natl Compr Canc Netw. 2006 Nov;4(10):971-9
17112447
Breast Cancer Res Treat. 2008 Jan;107(1):15-24
18043895
J Clin Oncol. 2007 Nov 20;25(33):5187-93
18024866
Cancer Res. 1988 Apr 15;48(8):2304-8
3349495
Breast Cancer Res Treat. 2007 Jan;101(1):113-21
17115111
Lancet. 2006 Feb 18;367(9510):595-604
16488803
J Clin Oncol. 2005 Dec 20;23(36):9312-8
16361630